v3.26.3
Fair Value Measurements - Schedule of Recurring Fair Value Measurements Using Significant Unobservable Inputs (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Derivative Liabilities Embedded Derivative | 2029 Notes | 2029 Embedded Derivative        
Liabilities Measured on Recurring Basis        
As of beginning balance $ 152,904 $ 48,093 $ 83,904 $ 51,819
Additions 0   0  
Payments     0  
Changes in fair value (28,152) 16,422 40,848 12,696
As of ending balance 124,752 64,515 124,752 64,515
Derivative Liabilities Embedded Derivative | 2025 Notes | 2029 Embedded Derivative        
Liabilities Measured on Recurring Basis        
As of beginning balance   1,363   2,915
Changes in fair value   322   (1,230)
As of ending balance   1,685   1,685
ImThera Contingent Consideration Arrangements Liability        
Liabilities Measured on Recurring Basis        
As of beginning balance 42,121 87,927 92,075 84,218
Additions 0   0  
Payments     (60,458)  
Changes in fair value 3,273 1,755 13,777 5,464
As of ending balance 45,394 89,682 45,394 89,682
ImThera Contingent Consideration Arrangements Liability | Income Statement Location [Axis]: us-gaap:CostOfGoodsAndServicesSold        
Liabilities Measured on Recurring Basis        
Changes in fair value   $ 1,000 $ 3,300 $ 2,800
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]   Cost of sales Cost of sales Cost of sales
ImThera Contingent Consideration Arrangements Liability | Income Statement Location [Axis]: us-gaap:ResearchAndDevelopmentExpense        
Liabilities Measured on Recurring Basis        
Changes in fair value   $ 800 $ 10,400 $ 2,700
Fair Value, Liability, Recurring Basis, Unobservable Input Reconciliation, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]   Research and development Research and development Research and development
Derivative Assets Capped Calls | 2029 Notes | 2029 Capped Calls        
Assets Measured on Recurring Basis        
As of beginning period 57,293 $ 21,658 $ 36,551 $ 23,735
Additions 0   0  
Payment     0  
Changes in fair value (4,700) 6,353 16,042 4,276
As of ending period 52,593 28,011 52,593 28,011
Derivative Assets Capped Calls | 2025 Notes | 2029 Capped Calls        
Assets Measured on Recurring Basis        
As of beginning period   1,303   2,624
Changes in fair value   324   (997)
As of ending period   $ 1,627   $ 1,627
Investment in Convertible Notes Receivable        
Assets Measured on Recurring Basis        
As of beginning period 3,000   3,000  
Additions 1,167   1,167  
Payment     0  
Changes in fair value 0   0  
As of ending period $ 4,167   $ 4,167